Market/Novel Tech Articles
Review of price tag for Spark Therapeutics’ gene therapy treatment (Luxturna, $850,000 per patient) suggests a discount of up to 90% in certain cases.
In a report published by the US Institute for Clinical and Economic Review (ICER), healthcare experts stated that the recently approved gene therapy for Leber’s congenital amaurosis (LCA), “Luxturna voretigene neparvovec-rzyl”, from Spark Therapeutics Inc. (NASDAQ:ONCE), may require substantial discounts in order to be cost-effective. The new drug, developed by Spark Therapeutics, a gene therapy […]Read full story
Spark Therapeutics proposes price tag of $850,000 per patient for new gene therapy treatment
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has indicated a price tag of $850,000 per patient for its new gene therapy treatment, “LUXTURNA” (voretigene neparvovec). The treatment, designed for patients with vision loss due to Leber’s congenital amurosis, is undergoing regulatory submission in the United States and Europe. According to the […]Read full story
French biopharmaceutical company, GenSight Biologics, reports long-term data for gene therapy treatment of LHON
GenSight Biologics (Euronext: SIGHT) have reported 30 months of follow-up data from a Phase I/II clinical trial with their treatment (GS010) in patients with Leber hereditary optic neuropathy (LHON). The results of the study indicate that long-term sustained gains in visual acuity appear to persist for 30 months following a single intravitreal injection in subjects […]Read full story